Quince Therapeutics (QNCX) announced the poster presentation of patient-reported walking capacity in children with Ataxia-Telangiectasia at the 54th Child Neurology Society, CNS, Annual Meeting. The objective of the data analysis was to describe the pattern of age-related walking capacity loss in patients with A-T and compare the subjective walking scale to the two measures – International Cooperative Ataxia Rating Scale and Rescored modified ICARS – used in the current Phase 3 NEAT clinical trial of the company’s lead asset, encapsulated dexamethasone sodium phosphate.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX:
- Quince Therapeutics: Buy Rating Affirmed Amid Promising Phase 3 Trial and Strong Financial Position
- Quince Therapeutics Amends Credit Facility Agreement
- Quince Therapeutics price target lowered to $8 from $9 at Citizens JMP
- Quince Therapeutics Reports Q2 2025 Financial Results
- Quince Therapeutics reports Q2 EPS (34c), consensus (23c)